Analysis of the risk factors for febrile neutropenia in patients with bone and soft tissue sarcoma.
Although systemic chemotherapy is inevitably selected as the modality of treatment for high-grade bone and soft tissue sarcoma (BSTS), limited information is available regarding febrile neutropenia (FN). FN incidence, blood culture results and risk factors were analyzed in 35 patients with high-grade BSTS. FN occurred in 51% of the patients and 24% of the courses of systemic chemotherapy. Culture results indicated pathogen in only 33.3% of patients who had FN. Methicillin-resistant Staphylococcus epidermidis and methicillin-resistant Staphylococcus aureus were frequently observed. Body weight of less than 61.0 kg and a tumor originating from the bone in a patient-based analysis, and serum albumin <4.2 g/dl and having a source of infection in a course-based analysis were independent risk factors for FN. Considerably high risks for FN during chemotherapy for BSTS were confirmed. The risk factors presented here appeared to differ from those in previously reported guidelines.